XML 54 R29.htm IDEA: XBRL DOCUMENT v3.20.4

SHAREHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2020

Share-based Payment Arrangement [Abstract]

Schedule of employee and non-employee shares options activity

A summary of employee and non-employee shares options activity during the fiscal year ended 2020 is as follows:

		Number				Average exercise price				Average remaining contractual life (years)				Aggregate intrinsic value (in thousands)
Options outstanding at the beginning of the year			74,713			$	41.6				6.34			$	135
Granted			—				—				—				—
Exercised			—				—				—				—
Forfeited			(5,107	)			91.59				—				—
Options outstanding at the end of the year			69,606			$	37.9				5.59			$	—
Options exercisable at the end of the year			52,997			$	43.76				4.94			$	—

Schedule of employee and non-employee RSUs activity

A summary of employee and non-employee RSUs activity during the fiscal year ended 2020 is as follows:

		Number of shares underlying outstanding RSUs				Weighted- average grant date fair value
Unvested RSUs at the beginning of the year			62,378				44.61
Granted			1,266,185				1.44
Vested			(63,111	)			7.83
Forfeited			(14,141	)			6.05
Unvested RSUs at the end of the year			1,251,311				3.20

Schedule of options and RSUs outstanding

The number of options and RSUs outstanding as of December 31, 2020 is set forth below, with options separated by range of exercise price:

Range of exercise price		Options and RSUs Outstanding as of December 31, 2020				Weighted average remaining contractual life (years) (1)				Options Exercisable as of December 31, 2020				Weighted average remaining contractual life (years) (1)
RSUs only			1,251,311				—				—				—
$5.37			12,425				8.24				5,435				8.24
$20.42- $33.75			36,292				5.26				27,598				4.60
$37.14-$38.75			9,992				2.99				9,992				2.99
$50-$52.5			8,231				6.43				7,306				6.44
$182.5-$524.25			2,666				4.84				2,666				4.84
			1,320,917				5.59				52,997				4.94

(1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

Schedule of non-cash share-based compensation expense

The Company recognized non-cash share-based compensation expense in the consolidated statements of operations as follows (in thousands):

		Year Ended December 31,
		2020				2019				2018
Cost of revenues		$	8			$	13			$	16
Research and development, net			136				204				435
Sales and marketing, net			163				166				467
General and administrative			442				725				1,848
Total		$	749			$	1,108			$	2,766

Schedule of warrants outstanding and exercisable

The following table summarizes information about warrants outstanding and exercisable as of December 31, 2020:

Issuance date		Warrants outstanding				Exercise price per warrant				Warrants outstanding and exercisable			Contractual term
		(number)								(number)
December 31, 2015 (1)			4,771			$	7.500				4,771		See footnote (1)
November 1, 2016 (2)			97,496			$	118.750				97,496		November 1, 2021
December 28, 2016 (3)			1,908			$	7.500				1,908		See footnote (1)
November 20, 2018 (4)			126,839			$	7.500				126,839		November 20, 2023
November 20, 2018 (5)			106,680			$	9.375				106,680		November 15, 2023
February 25, 2019 (6)			45,600			$	7.187				45,600		February 21, 2024
April 5, 2019 (7)			408,457			$	5.140				408,457		October 7, 2024
April 5, 2019 (8)			49,015			$	6.503				49,015		April 3, 2024
June 5, 2019 and June 6, 2019 (9)			1,464,665			$	7.500				1,464,665		June 5, 2024
June 5, 2019 (10)			87,880			$	9.375				87,880		June 5, 2024
June 12, 2019 (11)			416,667			$	6.000				416,667		December 12, 2024
June 10, 2019 (12)			50,000			$	7.500				50,000		June 10, 2024
February 10, 2020 (13)			3,768,500			$	1.250				4,343,500		February 10, 2025
February 10, 2020 (14)			336,000			$	1.5625				336,000		February 10, 2025
July 6, 2020 (15)			2,469,139			$	1.76				2,469,139		July 2, 2025
July 6, 2020 (16)			296,297				2.2781				296,297		July 2, 2025
December 3, 2020 (17)			4,184,832				1.34				4,184,832		June 8, 2026
December 3, 2020 (18)			334,787				1.7922				334,787		June 8, 2026
			14,249,533								14,249,533

(1) Represents warrants for ordinary shares issuable upon an exercise price of $7.5 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2020.

	(2)	Represents warrants issued as part of the Company’s follow-on offering in November 2016. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate.
	(3)	Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.
	(4)	Represents common warrants that were issued as part of the Company’s follow-on offering in November 2018. As of September 30, 2019, warrants to purchase an aggregate 1,651,537 ordinary shares had been exercised.

	(5)	Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on offering in November 2018.
	(6)	Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on offering in February 2019.
	(7)	Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.
	(8)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering.
	(9)	Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019 and June 6, 2019, respectively.
	(10)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants.
	(11)	Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.
	(12)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants.
	(13)	Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020.
	(14)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering.
	(15)	Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020
	(16)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.
	(17)	Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020
	(18)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement.

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

+ Details

Name:	us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

+ Details

Name:	us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration